On CNBC's "Options Action," traders answered a question from a viewer about Pfizer Inc. PFE. He was interested to know their opinion about a purchase of the January $40 call option.
Carter Worth thinks that is a really good bet. There is enough time and he would be comfortably long. The stock had a big day on Friday on expanding volume, and it was news-related.
Mike Khouw also likes the trade and the timing. The stock has low volatility and low implied volatility, so the options themselves tend not to cost that much, said Khouw.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.